statement of devaition or variation of funds for q ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has filed its quarterly compliance statement confirming there has been no deviation or variation from the originally stated use of funds across three tranches of preferential equity issues raised between March 2021 and July 2022. The total amount raised across these three tranches is approximately Rs 5.34 crore (Rs 2.64 crore in March 2021, Rs 1.38 crore in February 2022, and Rs 1.32 crore in July 2022). During Q1 FY26 (quarter ended 30 June 2025), only Rs 14.57 lakh was utilised from the third tranche, while no funds were deployed from the first two tranches during the quarter. The unutilised balance is parked as a fixed deposit in an escrow account with Bank of Baroda. The funds were originally meant for capital revamping, marketing infrastructure, civil work, plant and machinery, working capital, technology investments, and general corporate purposes.
This is a routine compliance filing with no negative implications, confirming funds raised through preferential issues have been used as originally approved. However, investors may note the slow pace of fund deployment, with significant portions raised 3–4 years ago still sitting unutilised, which could raise questions about execution timelines for the company's growth plans.